Resultados de búsqueda - Neil P. Shah

Limitar resultados
  1. 1
    Loss of Response to Imatinib: Mechanisms and Management

    Loss of Response to Imatinib: Mechanisms and Management por Neil P. Shah

    Publicado 2005
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  2. 2
    FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors

    FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors por Catherine C. Smith, Kevin Lin, Adrian Stecuła, Andrej Šali, Neil P. Shah

    Publicado 2015
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  3. 3
    Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure–response analysis of a Phase III study

    Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure–response analysis of a Phase III study por Neil P. Shah, Wang, Amit Roy, Andreas Hochhaus, Kantarjian, Tai‐Tsang Chen

    Publicado 2013
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  4. 4
    Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance

    Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance por Michael R. Burgess, Brian J. Skaggs, Neil P. Shah, Francis Y. Lee, Charles L. Sawyers

    Publicado 2005
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  5. 5
    The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle

    The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle por Jeremy B. M. Jowett, Vicente Planelles, Betty Poon, Neil P. Shah, M L Chen, I S Chen

    Publicado 1995
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  6. 6
    Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

    Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia por Neil P. Shah, John Nicoll, Bhushan Nagar, M. Gorre, Ronald Paquette, John Kuriyan, Charles L. Sawyers

    Publicado 2002
    Enlace del recurso Enlace del recurso
    Carta
    Agregar a favoritos
    Guardado en:
  7. 7
    Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment

    Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment por Su Chu, Helen Xu, Neil P. Shah, David S. Snyder, Stephen J. Forman, Charles L. Sawyers, Ravi Bhatia

    Publicado 2004
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  8. 8
    Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

    Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop por S. A. Roumiantsev, Neil P. Shah, M. Gorre, John Nicoll, Bradley Brasher, Charles L. Sawyers, Richard A. Van Etten

    Publicado 2002
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  9. 9
    Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis

    Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis por Neil P. Shah, Corynn Kasap, Christopher Weier, Minna Balbas, John Nicoll, Eric Bleickardt, Claude Nicaise, Charles L. Sawyers

    Publicado 2008
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  10. 10
    Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency

    Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency por Neil P. Shah, Brian J. Skaggs, Susan Branford, Timothy P. Hughes, John Nicoll, Ronald Paquette, Charles L. Sawyers

    Publicado 2007
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  11. 11
    Equally Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase Conformations

    Equally Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase Conformations por Markus A. Seeliger, Pratistha Ranjitkar, Corynn Kasap, Yibing Shan, David E. Shaw, Neil P. Shah, John Kuriyan, Dustin J. Maly

    Publicado 2009
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  12. 12
    Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD

    Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD por Catherine C. Smith, Elisabeth A. Lasater, Xiaotian Zhu, Kimberly C. Lin, Whitney Stewart, Lauren E. Damon, Sara Salerno, Neil P. Shah

    Publicado 2013
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  13. 13
    Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity

    Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity por Charles A. Schiffer, Jorge E. Cortés, Andreas Hochhaus, Giuseppe Saglio, Philipp le Coutre, Kimmo Porkka, Satu Mustjoki, Hesham Mohamed, Neil P. Shah

    Publicado 2016
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  14. 14
    Clinical features of pulmonary arterial hypertension in patients receiving dasatinib

    Clinical features of pulmonary arterial hypertension in patients receiving dasatinib por Neil P. Shah, Nicola Wallis, Harrison W. Farber, Michael J. Mauro, Robert A. Wolf, Daniele Mattei, Mausumee Guha, Delphine Réa, Andrew J. Peacock

    Publicado 2015
    Enlace del recurso Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  15. 15
    Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia

    Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia por Simona Soverini, Susan Branford, Franck E. Nicolini, Moshe Talpaz, Michael W. Deininger, Giovanni Martinelli, Martin C. Müller, Jerald P. Radich, Neil P. Shah

    Publicado 2013
    Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  16. 16
    Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance

    Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance por Meenu Kesarwani, Erika Huber, Zachary Kincaid, Chris R. Evelyn, Jacek Biesiada, Mark Rance, Mahendra Thapa, Neil P. Shah, Jarek Meller, Yi Zheng, Mohammad Azam

    Publicado 2015
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  17. 17
    Dasatinib or high‐dose imatinib for chronic‐phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily

    Dasatinib or high‐dose imatinib for chronic‐phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily por Hagop M. Kantarjian, Ricardo Pasqüini, Vincent Lévy, Saengsuree Jootar, Jerzy Hołowiecki, Nelson Hamerschlak, Timothy P. Hughes, Eric Bleickardt, David Dejardin, Jorge E. Cortés, Neil P. Shah

    Publicado 2009
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  18. 18
    Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy

    Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy por Alexander A. Warkentin, Michael S. Lopez, Elisabeth A. Lasater, Kimberly C. Lin, Bai‐Liang He, Anskar YH Leung, Catherine C. Smith, Neil P. Shah, Kevan M. Shokat

    Publicado 2014
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  19. 19
    Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034

    Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034 por Neil P. Shah, Philippe Rousselot, Charles A. Schiffer, Delphine Réa, Jorge E. Cortés, Jorge Milone, Hesham Mohamed, Diane Healey, Hagop M. Kantarjian, Andreas Hochhaus, Giuseppe Saglio

    Publicado 2016
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  20. 20
    Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia

    Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia por Timothy P. Hughes, Pierre Laneuville, Philippe Rousselot, David S. Snyder, Delphine Réa, Neil P. Shah, Dávid Paár, Elisabetta Abruzzese, Andreas Hochhaus, Jeffrey H. Lipton, Jorge E. Cortés

    Publicado 2018
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:

Herramientas de búsqueda: